SK17302001A3 - Tiazolové zlúčeniny a farmaceutické zmesi na inhibíciu proteínkináz a na metódy ich využívania - Google Patents

Tiazolové zlúčeniny a farmaceutické zmesi na inhibíciu proteínkináz a na metódy ich využívania Download PDF

Info

Publication number
SK17302001A3
SK17302001A3 SK1730-2001A SK17302001A SK17302001A3 SK 17302001 A3 SK17302001 A3 SK 17302001A3 SK 17302001 A SK17302001 A SK 17302001A SK 17302001 A3 SK17302001 A3 SK 17302001A3
Authority
SK
Slovakia
Prior art keywords
amino
aryl
heteroaryl
substituted
pharmaceutically acceptable
Prior art date
Application number
SK1730-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Shao Song Chu
Larry Andrew Alegria
Steven Lee Bender
Suzanne Pritchett Benedict
Allen J. Borchardt
Robert Steven Kania
Mitchell David Nambu
Anna Marie Tempczyk-Russell
Sepehr Sarshar
Dilip Bhumralkar
Zhengwei Peng
Yi Michelle Yang
Original Assignee
Agouron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc. filed Critical Agouron Pharmaceuticals, Inc.
Publication of SK17302001A3 publication Critical patent/SK17302001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK1730-2001A 1999-06-04 2000-06-02 Tiazolové zlúčeniny a farmaceutické zmesi na inhibíciu proteínkináz a na metódy ich využívania SK17302001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13781099P 1999-06-04 1999-06-04
PCT/US2000/015188 WO2000075120A1 (en) 1999-06-04 2000-06-02 Diaminothiazoles and their use for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
SK17302001A3 true SK17302001A3 (sk) 2004-01-08

Family

ID=22479135

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1730-2001A SK17302001A3 (sk) 1999-06-04 2000-06-02 Tiazolové zlúčeniny a farmaceutické zmesi na inhibíciu proteínkináz a na metódy ich využívania

Country Status (34)

Country Link
US (1) US6620828B2 (de)
EP (1) EP1181283B1 (de)
JP (1) JP2003501420A (de)
KR (1) KR20020015333A (de)
CN (1) CN1359380A (de)
AP (1) AP2001002341A0 (de)
AT (1) ATE288424T1 (de)
AU (1) AU778071B2 (de)
BG (1) BG106276A (de)
BR (1) BR0011585A (de)
CA (1) CA2371158A1 (de)
CZ (1) CZ20014213A3 (de)
DE (1) DE60017894T2 (de)
EA (1) EA200101268A1 (de)
EE (1) EE200100659A (de)
ES (1) ES2234628T3 (de)
HR (1) HRP20020008A2 (de)
HU (1) HUP0202897A3 (de)
IL (1) IL146094A0 (de)
IS (1) IS6183A (de)
MA (1) MA25530A1 (de)
MX (1) MXPA01012483A (de)
NO (1) NO20015045L (de)
NZ (1) NZ514881A (de)
OA (1) OA11959A (de)
PE (1) PE20010211A1 (de)
PL (1) PL352714A1 (de)
SK (1) SK17302001A3 (de)
SV (1) SV2002000096A (de)
UA (1) UA71971C2 (de)
UY (1) UY26190A1 (de)
WO (1) WO2000075120A1 (de)
YU (1) YU85601A (de)
ZA (1) ZA200108291B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CN1158269C (zh) * 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2002231139B2 (en) 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
CN1638776A (zh) * 2001-06-08 2005-07-13 西托维亚公司 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物
WO2003062215A1 (en) * 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
US20050239852A1 (en) * 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
ZA200503967B (en) 2002-11-01 2006-11-29 Takeda Pharmaceutical Agent for preventing or treating neuropathy
EP1597256A1 (de) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclylsubstituierte aminothiazolderivate als proteinkinaseinhibitoren
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
UA84420C2 (ru) 2003-04-11 2008-10-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
EP1644323B1 (de) * 2003-07-07 2015-03-18 Georgetown University Histondeacetylaseinhibitoren und verfahren zu deren anwendung
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
EP2060270A3 (de) * 2003-10-16 2009-12-09 Imclone LLC Fibroblasten-Wachstumsfaktorrezeptor-1-Inhibitoren und Behandlungsverfahren damit
PT1709019E (pt) * 2004-01-12 2007-08-27 Serono Lab Derivados de tiazol e sua utilização
WO2005108370A1 (ja) * 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
WO2006017216A1 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Histone deacetylase inhibitors
WO2006125803A1 (en) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Thiazole derivatives and use thereof
AU2006251159B2 (en) * 2005-05-24 2011-09-22 Merck Serono Sa Thiazole derivatives and use thereof
EP1945632B1 (de) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterozyklische modulatoren von atp-bindenden kassettentransportern
AU2012244242B2 (en) * 2005-12-28 2015-05-21 Vertex Pharmaceuticals Incorporated 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
EP2016065B1 (de) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropan-carboxamid-derivate und verwandte verbindungen als modulatoren von atp-bindungskassettentransportern zur behandlung von zystischer fibrose
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
US8748627B2 (en) * 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN101384568B (zh) * 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP5367563B2 (ja) 2006-03-30 2013-12-11 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
UA95298C2 (ru) 2006-07-07 2011-07-25 Бьёрингер Ингельхайм Интернациональ Гмбх Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2789606B1 (de) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulatoren von CFTR
CA2692379A1 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
EP3683218B1 (de) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Feste formen von 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesäure
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20110098296A1 (en) * 2007-12-13 2011-04-28 George Adjabeng Thiazole And Oxazole Kinase Inhibitors
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
PT2387395E (pt) 2009-01-16 2015-02-04 Rigel Pharmaceuticals Inc Inibidores de axl para utilização em terapia de combinação para prevenir, tratar ou gerir cancro metastático
JPWO2011048936A1 (ja) 2009-10-19 2013-03-07 大正製薬株式会社 アミノチアゾール誘導体
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (de) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibitoren der B-Raf Kinase
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2013161919A1 (ja) * 2012-04-26 2013-10-31 小野薬品工業株式会社 Ｔｒｋ阻害化合物
SG10201700808UA (en) 2013-02-19 2017-02-27 Ono Pharmaceutical Co Trk-INHIBITING COMPOUND
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CA3174516A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
SG11201703963QA (en) 2014-11-18 2017-06-29 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography
WO2017075312A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
US11001564B2 (en) * 2016-09-13 2021-05-11 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
CN111233786B (zh) * 2020-02-04 2021-11-26 中国人民解放军军事科学院军事医学研究院 含五元杂环的苯磺酰胺类化合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
AU558132B2 (en) 1981-05-27 1987-01-22 Labatt Brewing Co. Ltd. Malt sterilisation with hydrogen peroxide
EP0218728A1 (de) 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Phenylenabkömmlinge
US5409930A (en) * 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2130196A1 (en) 1992-03-24 1993-09-30 Jose Luis Castro Pineiro Benzodiazepine derivatives
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de) 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
CZ294097B6 (cs) 1995-02-02 2004-10-13 Smithklineábeechamáplc Indolový derivátŹ způsob jeho přípravy a farmaceutická kompozice s jeho obsahem
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6514971B1 (en) 1996-03-15 2003-02-04 Zeneca Limited Cinnoline derivatives and use as medicine
DE69709493T2 (de) 1996-06-27 2002-10-31 Pfizer Inc., New York Substituierte Indazolderivate
PL332187A1 (en) 1996-09-04 1999-08-30 Pfizer Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
CN1158269C (zh) * 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
BR9813938A (pt) 1997-11-04 2000-09-26 Pfizer Prod Inc Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4
CA2309150A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them

Also Published As

Publication number Publication date
IL146094A0 (en) 2002-07-25
BR0011585A (pt) 2002-03-19
UA71971C2 (en) 2005-01-17
DE60017894T2 (de) 2005-12-29
ZA200108291B (en) 2002-12-24
OA11959A (en) 2006-04-17
MXPA01012483A (es) 2002-07-30
EP1181283A1 (de) 2002-02-27
KR20020015333A (ko) 2002-02-27
EP1181283B1 (de) 2005-02-02
US20020025976A1 (en) 2002-02-28
SV2002000096A (es) 2002-06-07
ES2234628T3 (es) 2005-07-01
IS6183A (is) 2001-11-29
AU5725400A (en) 2000-12-28
HUP0202897A3 (en) 2004-12-28
AP2001002341A0 (en) 2001-12-31
EE200100659A (et) 2003-02-17
YU85601A (sh) 2004-09-03
MA25530A1 (fr) 2002-10-01
AU778071B2 (en) 2004-11-11
CA2371158A1 (en) 2000-12-14
PL352714A1 (en) 2003-09-08
BG106276A (bg) 2002-10-31
NO20015045L (no) 2002-02-04
WO2000075120A1 (en) 2000-12-14
UY26190A1 (es) 2000-12-29
DE60017894D1 (de) 2005-03-10
PE20010211A1 (es) 2001-03-16
EA200101268A1 (ru) 2002-06-27
HUP0202897A2 (hu) 2002-12-28
JP2003501420A (ja) 2003-01-14
NO20015045D0 (no) 2001-10-17
NZ514881A (en) 2003-10-31
ATE288424T1 (de) 2005-02-15
CN1359380A (zh) 2002-07-17
CZ20014213A3 (cs) 2002-04-17
HRP20020008A2 (en) 2004-02-29
US6620828B2 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
SK17302001A3 (sk) Tiazolové zlúčeniny a farmaceutické zmesi na inhibíciu proteínkináz a na metódy ich využívania
US6462069B2 (en) Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases
KR102043337B1 (ko) 글리코시다제 저해제
Kim et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities
US9163007B2 (en) 5-substituted indazoles as kinase inhibitors
RO119463B1 (ro) Derivaţi de 4-aminotiazol şi utilizarea lor ca inhibitori ai cdk
NO322507B1 (no) Indazolforbindelser og farmasøytisk materiale derav for inhibering av proteinkinaser, og bruk derav som et medikament.
CN101790526A (zh) 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
JP2007532563A5 (de)
HUE027263T2 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
US6566363B2 (en) Pyrazole-thiazole compounds, pharmaceutical compositions containing them
JP2008545690A (ja) 新規化合物
US20040176431A1 (en) Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives and pharmaceutical compositions, and methods for their use
ES2238463T3 (es) Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
CZ20001285A3 (cs) Substituované 4-aminothiazol-2-ylové sloučeniny jako inhibitory cyklin-dependentních kinas